We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Benztropine for Cocaine Craving - 2

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000333
First Posted: September 21, 1999
Last Update Posted: February 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Washington D.C. Veterans Affairs Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Condition Intervention Phase
Cocaine-Related Disorders Drug: Benztropine Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Evaluation of Efficacy of Benztropine for Cocaine Craving

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Stimulated and non-stimulated craving

Estimated Enrollment: 0
Actual Study Start Date: May 2001
Study Completion Date: April 2003
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 48 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000333


Locations
United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Washington D.C. Veterans Affairs Medical Center
Investigators
Principal Investigator: Steven Deutsch, M.D. Washington D.C. Veterans Affairs Medical Center
  More Information

ClinicalTrials.gov Identifier: NCT00000333     History of Changes
Other Study ID Numbers: NIDA-3-0009-2
Y01-3-0009-2
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: February 24, 2017
Last Verified: December 2002

Studies a U.S. FDA-regulated Drug Product: Yes

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Cocaine
Benztropine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents